MedTrace Logo

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

NCT04409327 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-02-10

No results posted yet for this study

Summary

The purpose of this study is to determine if prophylaxis with RTB101 decreases the severity of laboratory-confirmed COVID-19 among adults ≥ 65 years who reside in a nursing homes in which one or more residents or staff have laboratory-confirmed COVID-19

Conditions

  • COVID19

Interventions

DRUG

RTB101

Oral RTB101 10 mg hard gelatin capsule once daily for 4 weeks

DRUG

Placebo

Oral matching placebo once daily for 4 weeks

Sponsors & Collaborators

  • Restorbio Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Restorbio Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-11
Primary Completion
2020-12-27
Completion
2021-01-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04409327 on ClinicalTrials.gov